Decreasing the Risk of Lead Migration in Occipital Nerve Stimulation for Cluster Headache Using Dedicated Leads
Abstract
OBJECTIVE: Our aim was to assess the effectiveness and complication rate of occipital nerve stimulation (ONS) using a recently developed anchoring lead dedicated to ONS in patients treated for refractory chronic cluster headache (rCCH). MATERIALS AND METHODS: Patients with rCCH were included in a prospective multicenter ONS registry from 2019 to 2024 and treated by ONS using anchored ONS-dedicated leads. The effectiveness of ONS was evaluated by the frequency of chronic cluster headache (CCH) attacks, abortive and preventive medication use, quality of life (EuroQol-5 Dimensions scale), and the functional (Headache Impact Test-6) and emotional (Hospital Anxiety and Depression Scale) impacts. Complications were monitored, focusing on electrode migration, device malfunction, infections, and local pain. RESULTS: Overall, 40 (16 women, mean age 46 years) and 24 patients were followed for one and two years after ONS, respectively. The mean weekly attack frequency significantly decreased, from 24.3 before ONS to 12.7 (p = 0.006) at one year and to 11.7 (p = 0.002) at two years. Functional and emotional impacts and quality of life significantly improved. During the follow-up period, 16 patients experienced device-related complications, including infection (7.5%), lead migration (5%), hardware dysfunction (15%), and pain at the lead insertion site (12.5%). CONCLUSION: ONS using ONS-dedicated leads showed similar effectiveness, while also presenting a low risk of migration, to ONS using other leads reported in previous studies. CLINICAL TRIAL REGISTRATION: The Clinicaltrials.gov registration number for the study is NCT01842763.
Related
- Effect of stimulation parameters for transcranial temporal interference stimulation to enhance occipital alpha-oscillations in healthy participants
- Brain representations of visual short-term memories during healthy human aging: occipital decline and frontoparietal compensation
- France’s Pesticide Load Index: Decreasing Ecotoxicity, Persistent Human Toxicity, Rising Concern For Environmental Fate
- Importance of the gonococcal MtrCDE efflux pump system in decreasing bacterial susceptibility to zoliflodacin: implications for future clinical treatment of gonorrhea
- Lack of vision shifts occipital dynamics toward a frontal-like regime and enhances top-down connectivity
BibTeX
@article{messaoudi2026decreasing,
title = {{Decreasing the Risk of Lead Migration in Occipital Nerve Stimulation for Cluster Headache Using Dedicated Leads}},
author = {Samia Messaoudi and Aurélie Leplus and Anne Donnet and Jean Regis and Anne Balossier and Sylvie Raoul and Geneviève Demarquay and Émile Simon and Xavier Moisset and Denis Sinardet and Jimmy Voirin and Sophie Colnat-Coulbois and Michel Lanteri-Minet and Denys Fontaine},
journal = {Neuromodulation},
year = {2026},
month = oct,
doi = {10.1016/j.neurom.2026.01.009},
url = {https://hal.science/hal-05794368v1},
note = {CC BY},
}
RIS
TY - JOUR
TI - Decreasing the Risk of Lead Migration in Occipital Nerve Stimulation for Cluster Headache Using Dedicated Leads
AU - Samia Messaoudi
AU - Aurélie Leplus
AU - Anne Donnet
AU - Jean Regis
AU - Anne Balossier
AU - Sylvie Raoul
AU - Geneviève Demarquay
AU - Émile Simon
AU - Xavier Moisset
AU - Denis Sinardet
AU - Jimmy Voirin
AU - Sophie Colnat-Coulbois
AU - Michel Lanteri-Minet
AU - Denys Fontaine
PY - 2026
DA - 2026/10/12
JO - Neuromodulation
DO - 10.1016/j.neurom.2026.01.009
UR - https://hal.science/hal-05794368v1
AB - OBJECTIVE: Our aim was to assess the effectiveness and complication rate of occipital nerve stimulation (ONS) using a recently developed anchoring lead dedicated to ONS in patients treated for refractory chronic cluster headache (rCCH). MATERIALS AND METHODS: Patients with rCCH were included in a prospective multicenter ONS registry from 2019 to 2024 and treated by ONS using anchored ONS-dedicated leads. The effectiveness of ONS was evaluated by the frequency of chronic cluster headache (CCH) attacks, abortive and preventive medication use, quality of life (EuroQol-5 Dimensions scale), and the functional (Headache Impact Test-6) and emotional (Hospital Anxiety and Depression Scale) impacts. Complications were monitored, focusing on electrode migration, device malfunction, infections, and local pain. RESULTS: Overall, 40 (16 women, mean age 46 years) and 24 patients were followed for one and two years after ONS, respectively. The mean weekly attack frequency significantly decreased, from 24.3 before ONS to 12.7 (p = 0.006) at one year and to 11.7 (p = 0.002) at two years. Functional and emotional impacts and quality of life significantly improved. During the follow-up period, 16 patients experienced device-related complications, including infection (7.5%), lead migration (5%), hardware dysfunction (15%), and pain at the lead insertion site (12.5%). CONCLUSION: ONS using ONS-dedicated leads showed similar effectiveness, while also presenting a low risk of migration, to ONS using other leads reported in previous studies. CLINICAL TRIAL REGISTRATION: The Clinicaltrials.gov registration number for the study is NCT01842763.
SN - 1094-7159
SN - 1525-1403
ER -